Nonprofit scientific research organization IAVI announced on Wednesday that it has received USD26.7m from the Defense Threat Reduction Agency (DTRA) of the US Department of Defense (DoD) to develop its recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate in partnership with Merck.
Under an agreement, DTRA will facilitate the partnership's vaccine candidate's clinical development at IAVI's Vaccine Design and Development Laboratory (DDL) in Brooklyn, New York.
The partners plan to characterize the immune responses in animals and demonstrate the safety and efficacy profile of rVSVΔG-SARS-CoV-2 vaccination in animals. The nonclinical data will be essential to supplement the clinical data package and to inform the most effective use of the vaccine in an ongoing pandemic.
The partners' COVID-19 vaccine candidate, V590, is currently in preclinical development and clinical studies are planned to start this year. Merck will lead regulatory filings globally. Both will develop the vaccine and make it accessible globally, if approved.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients